On February 15, 2022, two invention patents filed by Clindata^® were published, namely "Method, System and Equipment for Generating Clinical Trial Development Plan" and "Method, Device and Readable Storage for Collecting Data Points of Clinical Trial Development Plan" medium". Previously, two PCT international invention patents applied for by Clindata Pharmaceutical Biotechnology (Beijing) Co., Ltd. (Clindata^®) received international application numbers and international application date notices, which also marked Clindata. The unique innovative concept of Clindata^® has been recognized internationally, and it has also opened the way for the internationalization of Clindata^®!

New drug development is divided into three stages, drug discovery, preclinical development and clinical development. In terms of time, cost and success rate, clinical R&D accounts for 65% to 75% of the entire new drug R&D. Therefore, the clinical development stage of new drug research and development determines the success rate of new drug research and development, the cycle of new drug research and development, and the cost of new drug research and development. The clinical research and development of new drug development is divided into six major processes, including planning, design, execution, analysis, reporting and interpretation. Planning is the formulation of strategies, and planning and design are the foundation and cornerstone of clinical research and development. From the perspective of global new drug research and development, there is still no good solution for the cornerstone of new drug research and development planning and design. Therefore, the strategy and design of new drug research and development have become the "neck" process of new drug research and development.

As the first innovative CRO in China that focuses on innovative strategies and design of innovative drugs for major diseases such as anti-tumor, Clindata^® is committed to solving difficult problems in clinical research, and these patents are our solutions. The future is promising, let's wait and see!